193 related articles for article (PubMed ID: 11850123)
1. Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer.
Yang ES; Maiorino CA; Roos BA; Knight SR; Burnstein KL
Mol Cell Endocrinol; 2002 Jan; 186(1):69-79. PubMed ID: 11850123
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.
Zhuang SH; Burnstein KL
Endocrinology; 1998 Mar; 139(3):1197-207. PubMed ID: 9492054
[TBL] [Abstract][Full Text] [Related]
4. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.
Kokontis JM; Hay N; Liao S
Mol Endocrinol; 1998 Jul; 12(7):941-53. PubMed ID: 9658399
[TBL] [Abstract][Full Text] [Related]
5. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Zhao XY; Peehl DM; Navone NM; Feldman D
Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte growth factor and vitamin D cooperatively inhibit androgen-unresponsive prostate cancer cell lines.
Qadan LR; Perez-Stable CM; Schwall RH; Burnstein KL; Ostenson RC; Howard GA; Roos BA
Endocrinology; 2000 Jul; 141(7):2567-73. PubMed ID: 10875259
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines.
Zhuang SH; Schwartz GG; Cameron D; Burnstein KL
Mol Cell Endocrinol; 1997 Jan; 126(1):83-90. PubMed ID: 9027366
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm.
Yang ES; Burnstein KL
J Biol Chem; 2003 Nov; 278(47):46862-8. PubMed ID: 12954644
[TBL] [Abstract][Full Text] [Related]
9. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1999 Mar; 140(3):1205-12. PubMed ID: 10067845
[TBL] [Abstract][Full Text] [Related]
10. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
[TBL] [Abstract][Full Text] [Related]
11. The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells.
Lu L; Schulz H; Wolf DA
BMC Cell Biol; 2002 Aug; 3():22. PubMed ID: 12188931
[TBL] [Abstract][Full Text] [Related]
12. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.
Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S
Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608
[TBL] [Abstract][Full Text] [Related]
13. GADD45gamma: a new vitamin D-regulated gene that is antiproliferative in prostate cancer cells.
Flores O; Burnstein KL
Endocrinology; 2010 Oct; 151(10):4654-64. PubMed ID: 20739400
[TBL] [Abstract][Full Text] [Related]
14. Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines.
Venkateswaran V; Klotz LH; Fleshner NE
Cancer Res; 2002 May; 62(9):2540-5. PubMed ID: 11980647
[TBL] [Abstract][Full Text] [Related]
15. The role of long-chain fatty-acid-CoA ligase 3 in vitamin D3 and androgen control of prostate cancer LNCaP cell growth.
Qiao S; Tuohimaa P
Biochem Biophys Res Commun; 2004 Jun; 319(2):358-68. PubMed ID: 15178414
[TBL] [Abstract][Full Text] [Related]
16. Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor.
Heisler LE; Evangelou A; Lew AM; Trachtenberg J; Elsholtz HP; Brown TJ
Mol Cell Endocrinol; 1997 Jan; 126(1):59-73. PubMed ID: 9027364
[TBL] [Abstract][Full Text] [Related]
17. Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31.
Moffatt KA; Johannes WU; Hedlund TE; Miller GJ
Cancer Res; 2001 Oct; 61(19):7122-9. PubMed ID: 11585744
[TBL] [Abstract][Full Text] [Related]
18. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
19. Mutually antagonistic effects of androgen and activin in the regulation of prostate cancer cell growth.
Carey JL; Sasur LM; Kawakubo H; Gupta V; Christian B; Bailey PM; Maheswaran S
Mol Endocrinol; 2004 Mar; 18(3):696-707. PubMed ID: 14684851
[TBL] [Abstract][Full Text] [Related]
20. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells.
Bao BY; Hu YC; Ting HJ; Lee YF
Oncogene; 2004 Apr; 23(19):3350-60. PubMed ID: 15048085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
